Q
QuantAbundanciaAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

24,787 signal articles · 256 in last 24h · 118,124 total before filter · latest 44m ago
256last 24h
1592last 7d
250● bullish (7d)
160● bearish (7d)
205publishers
AllMacro307Earnings652M&A92Regulatory28Product13Analyst24
✕ clear all filtersticker: ^IXICSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Nasdaq Drops as Chip Fever Breaks
Barrons.com98d agobearish
Nasdaq Drops as Chip Fever Breaks

Chip stocks got beat up after the latest inflation report. The tech-heavy Nasdaq was down 0.7%, the S&P 500 was down 0.2% while the Dow gained 56 points, or 0.1%. Notably, almost all major chip stocks were down, barring Nvidia.

Consumer Discretionary Stocks’ Long Winter Isn’t Over
Barrons.com98d agoneutral
Consumer Discretionary Stocks’ Long Winter Isn’t Over

Everything seems to be going well on Wall Street—but consumer stocks aren’t joining the party. Corporate earnings are booming, on pace for another quarter of double-digit percentage gains as the reporting season draws to a close. The State Street Consumer Discretionary Select Sector SPDR exchange-traded fund is down more than 1% since the start of the year—compared with gains of more than 8% and 15% for the S&P 500 and the Nasdaq, respectively.

What makes today's market 'completely different' from the 2000 bubble
Yahoo Finance Video98d agoneutralVIDEO
What makes today's market 'completely different' from the 2000 bubble

The "Big Short" investor Michael Burry raised concerns about the current state of the market (^DJI, ^IXIC, ^GSPC), writing that it has "jumped the shark" in a Substack post on Monday. Burry is best known for predicting the 2007 mortgage crisis. Yahoo Finance Executive Editor Brian Sozzi speaks with Senior Reporter Ines Ferré and B. Riley Wealth chief market strategist Art Hogan about the factors that may set this current market apart from the dot-com bubble era.

Dow Takes a Turn Lower
Barrons.com98d agoneutral
Dow Takes a Turn Lower

After opening little changed, the Dow slid further away from the widely watched 50,000 level. The blue-chip index was down 250 points, or 0.5%. The S&P 500 was down 0.5%, while the Nasdaq was down 0.8%.

Futures Recover Modestly From Inflation Report
Barrons.com98d agoneutral
Futures Recover Modestly From Inflation Report

Major stock indexes are settling in after a bit of volatility this morning. Dow futures have turned slightly positive, while S&P 500 futures are down 0.2%. Nasdaq futures are down 0.6%. Each of these indexes is in a place better than where they were immediately after the inflation report came out.

Inflation Picks Up Faster Than Expected in April
Barrons.com98d agoneutral
Inflation Picks Up Faster Than Expected in April

Consumer prices jumped more than expected in April, a sign that inflation is accelerating as the Iran war's fallout ripples through the economy. The headline consumer price index rose 0.6% from the previous month and 3.8% from a year earlier, above the 0.59% monthly gain and 3.7% annual increase economists had forecast, according to a survey by FactSet. The 3.8% annual increase marks the fastest pace of price growth since May 2023 and is also a notable jump from March, when CPI rose 3.3% year over year.

Stock Futures Dip After Hot CPI Reading
Barrons.com98d agoneutral
Stock Futures Dip After Hot CPI Reading

Stocks continued their downward drift after April inflation data came in higher than expected. S&P 500 futures declined 0.5%, and contracts tied to the tech-heavy Nasdaq 100 dropped nearly 1% right after the report.

IBT: NAV up 35.7% as biotech M&A boom drives outperformance
Proactive98d agobullishVIDEO
IBT: NAV up 35.7% as biotech M&A boom drives outperformance

International Biotechnology Trust (LSE:IBT) co-lead fund managers Ailsa Craig and Marek Poszepczynski tell Proactive's Stephen gunnion that the trust delivered NAV returns of 35.7% and share price gains of 39% in the six months to February — comfortably ahead of the Nasdaq Biotechnology Index's near-30% return. Five acquisitions completed during the period, with a further five since the interim end. Poszepczynski notes that around 40 portfolio companies have been acquired over the past five years as big pharma continues to rely on biotech for innovation. The sweetest spot for takeover activity, he says, is among companies approaching regulatory approval or commercial launch. Craig is also more optimistic on the political backdrop: "It really does feel like these political headwinds are now behind us," she says, pointing to easing concerns around US drug pricing reform and improving sentiment across the sector. For more interviews and market insights, visit the Proactive YouTube channel, give this video a like, subscribe to the channel and enable notifications for future content. #InternationalBiotechnologyTrust #Biotech #HealthcareInvesting #BiotechStocks #NasdaqBiotech #Pharma #BiotechInvesting #FDA #DrugDevelopment #MergersAndAcquisitions #HealthcareStocks #IPO #FundManagers #Investing #LifeSciences